Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone.
作者信息
Bloch Michael J, Basile Jan
机构信息
Division of General Internal Medicine, University of Nevada School of Medicine, Reno, NV, USA.
出版信息
J Clin Hypertens (Greenwich). 2008 Feb;10(2):160-3. doi: 10.1111/j.1751-7176.2008.07917.x.
Abstract
摘要
相似文献
1
Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone.托彻普对胆固醇酯转运蛋白的抑制作用会导致心血管事件增加：这种效应不太可能仅是血压升高所致。
J Clin Hypertens (Greenwich). 2008 Feb;10(2):160-3. doi: 10.1111/j.1751-7176.2008.07917.x.
2
Effects of torcetrapib in patients at high risk for coronary events.托彻普对冠心病高危患者的影响。
N Engl J Med. 2007 Nov 22;357(21):2109-22. doi: 10.1056/NEJMoa0706628. Epub 2007 Nov 5.
3
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.胆固醇酯转运蛋白抑制剂托彻普和脱靶毒性：一项使用新型胆固醇酯转运蛋白抑制剂（RADIANCE）试验进行成像评估动脉粥样硬化疾病变化的汇总分析
Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24.
4
On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.托彻普的靶标和非靶标药理学：当前的认识及其对结构-活性关系（SAR）、胆固醇酯转移蛋白（CETP）抑制剂的发现和开发的影响。
Drugs. 2012 Mar 5;72(4):491-507. doi: 10.2165/11599310-000000000-00000.
5
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.托彻普（torcetrapib）引起的血压升高与胆固醇酯转运蛋白（CETP）抑制无关，且伴有醛固酮循环水平升高。
Br J Pharmacol. 2008 Aug;154(7):1465-73. doi: 10.1038/bjp.2008.229. Epub 2008 Jun 9.
6
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.新型胆固醇酯转移蛋白抑制剂托彻普在阿托伐他汀治疗背景下对高密度脂蛋白胆固醇水平低于平均水平个体的疗效和安全性
J Am Coll Cardiol. 2006 Nov 7;48(9):1782-90. doi: 10.1016/j.jacc.2006.06.066.
7
Effect of torcetrapib on the progression of coronary atherosclerosis.托彻普对冠状动脉粥样硬化进展的影响。
N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26.
8
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.新型胆固醇酯转运蛋白抑制剂托彻普对高密度脂蛋白胆固醇水平低于平均水平个体的疗效及安全性
J Am Coll Cardiol. 2006 Nov 7;48(9):1774-81. doi: 10.1016/j.jacc.2006.06.067.
9
Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?在通过提高高密度脂蛋白和抑制胆固醇酯转运来降低心脏病风险方面，我们目前进展如何？
Curr Opin Cardiol. 2007 Jul;22(4):373-8. doi: 10.1097/HCO.0b013e3281fbd3c7.
10
The failure of torcetrapib: what have we learned?托彻普的失败：我们学到了什么？
Br J Pharmacol. 2008 Aug;154(7):1379-81. doi: 10.1038/bjp.2008.248. Epub 2008 Jun 9.
引用本文的文献
1
Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.循环胆固醇酯转移蛋白活性与社区人群心血管疾病发病的相关性。
Circulation. 2009 Dec 15;120(24):2414-20. doi: 10.1161/CIRCULATIONAHA.109.872705.
2
Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma.由于肝脂酶突变导致的高密度脂蛋白（HDL）水平升高并不会降低心血管疾病风险：对HDL理论的又一打击。
J Clin Endocrinol Metab. 2009 Apr;94(4):1081-3. doi: 10.1210/jc.2009-0344.
Zotero 插件